CLDX
Price:
$25.13
Market Cap:
$1.67B
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, wh...[Read more]
Industry
Biotechnology
IPO Date
1986-05-15
Stock Exchange
NASDAQ
Ticker
CLDX
According to Celldex Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.74. This represents a change of -37.08% compared to the average of -15.48 of the last 4 quarters.
The mean historical PE Ratio of Celldex Therapeutics, Inc. over the last ten years is -9.61. The current -9.74 PE Ratio has changed 10.03% with respect to the historical average. Over the past ten years (40 quarters), CLDX's PE Ratio was at its highest in in the March 2020 quarter at -0.57. The PE Ratio was at its lowest in in the September 2021 quarter at -29.99.
Average
-9.61
Median
-10.33
Minimum
-23.49
Maximum
-0.21
Discovering the peaks and valleys of Celldex Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.25%
Maximum Annual PE Ratio = -0.21
Minimum Annual Increase = -94.72%
Minimum Annual PE Ratio = -23.49
Year | PE Ratio | Change |
---|---|---|
2023 | -13.59 | -20.18% |
2022 | -17.02 | -27.55% |
2021 | -23.49 | 170.44% |
2020 | -8.69 | 1.25% |
2019 | -0.64 | 209.95% |
2018 | -0.21 | -94.72% |
2017 | -3.92 | 40.33% |
2016 | -2.80 | -76.63% |
2015 | -11.96 | -13.41% |
2014 | -13.82 | -41.66% |
The current PE Ratio of Celldex Therapeutics, Inc. (CLDX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-18.03
5-year avg
-12.69
10-year avg
-9.61
Celldex Therapeutics, Inc.’s PE Ratio is greater than IDEAYA Biosciences, Inc. (-12.24), less than AnaptysBio, Inc. (-2.42), less than MeiraGTx Holdings plc (-5.01), less than Keros Therapeutics, Inc. (-3.32), less than Homology Medicines, Inc. (-0.01), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Avidity Biosciences, Inc. (-13.79), greater than Revolution Medicines, Inc. (-13.06), greater than Day One Biopharmaceuticals, Inc. (-14.52), greater than SpringWorks Therapeutics, Inc. (-9.94), greater than Cytokinetics, Incorporated (-9.91), greater than DICE Therapeutics, Inc. (-22.94), greater than Edgewise Therapeutics, Inc. (-22.36), greater than Karuna Therapeutics, Inc. (-37.08), less than Dyne Therapeutics, Inc. (-8.21), greater than Crinetics Pharmaceuticals, Inc. (-15.54), less than ALX Oncology Holdings Inc. (-0.64), greater than Immatics N.V. (-11.79), less than BioAtla, Inc. (-0.37), less than Aerovate Therapeutics, Inc. (-0.89), less than Travere Therapeutics, Inc. (-3.79), less than Ventyx Biosciences, Inc. (-1.05), less than Cogent Biosciences, Inc. (-3.57),
Company | PE Ratio | Market cap |
---|---|---|
-12.24 | $2.19B | |
-2.42 | $422.65M | |
-5.01 | $482.21M | |
-3.32 | $676.88M | |
-0.01 | $3.02M | |
-17.73 | $8.19B | |
-13.79 | $3.74B | |
-13.06 | $8.09B | |
-14.52 | $1.28B | |
-9.94 | $2.74B | |
-9.91 | $5.73B | |
-22.94 | $2.27B | |
-22.36 | $2.80B | |
-37.08 | $12.60B | |
-8.21 | $2.44B | |
-15.54 | $5.00B | |
-0.64 | $96.52M | |
-11.79 | $847.43M | |
-0.37 | $30.00M | |
-0.89 | $75.07M | |
-3.79 | $1.49B | |
-1.05 | $160.51M | |
-3.57 | $868.23M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celldex Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Celldex Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Celldex Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Celldex Therapeutics, Inc. (CLDX)?
What is the highest PE Ratio for Celldex Therapeutics, Inc. (CLDX)?
What is the 3-year average PE Ratio for Celldex Therapeutics, Inc. (CLDX)?
What is the 5-year average PE Ratio for Celldex Therapeutics, Inc. (CLDX)?
How does the current PE Ratio for Celldex Therapeutics, Inc. (CLDX) compare to its historical average?